Exhibit 10.8 EMPLOYMENT AGREEMENT THIS AGREEMENT, made and entered into as of this 13th day of October, 1998, by and between Immucor, Inc., a Georgia corporation with its executive offices at 3130 Gateway Drive, Norcross, Georgia 30091 (herein...Employment Agreement • August 30th, 1999 • Immucor Inc • In vitro & in vivo diagnostic substances • Georgia
Exhibit 99.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this "AGREEMENT"), is made and entered into as of May 14, 2007, by and among Inverness Medical Innovations, Inc. a Delaware corporation (the "COMPANY"), and the purchasers...Registration Rights Agreement • May 15th, 2007 • Inverness Medical Innovations Inc • In vitro & in vivo diagnostic substances • New York
i) Kay is eligible to receive a cash performance bonus, to be paid each year at the same time bonuses are generally paid to other senior executives of the Company for the relevant fiscal year (but not later than April 30) of up to 35% of Kay's Base...Employment Agreement • March 29th, 2002 • Quidel Corp /De/ • In vitro & in vivo diagnostic substances • California
EXHIBIT 10.31Stock Purchase Agreement • February 9th, 2005 • Meridian Bioscience Inc • In vitro & in vivo diagnostic substances • Ohio
INDENTUREIndenture • December 2nd, 2003 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • New York
RECITALS:Distribution Agreement • November 5th, 2003 • Remote MDX Inc • In vitro & in vivo diagnostic substances • Utah
EXHIBIT 10.2(A) SEVERANCE AGREEMENT ------------------- THIS AGREEMENT, dated May , 1999, is made by and between Centocor, Inc. a Pennsylvania corporation (the "Company"), and _________ (the "Executive"). WHEREAS, the Company considers it essential to...Severance Agreement • May 17th, 1999 • Centocor Inc • In vitro & in vivo diagnostic substances • Pennsylvania
Exhibit 10.17 APPENDIX A TO PARTICIPATION AGREEMENTParticipation Agreement • April 1st, 2002 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances
ARTICLE ILease Agreement • May 15th, 2007 • Matritech Inc/De/ • In vitro & in vivo diagnostic substances • Massachusetts
EXHIBIT 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this "Agreement") is made and entered into as of January 10, 2005 (the "Effective Date"), by and between SCOLR Pharma, Inc., a Delaware corporation ("the Company"), and Alan M. Mitchel...Employment Agreement • January 11th, 2005 • SCOLR Pharma, Inc. • In vitro & in vivo diagnostic substances • Washington
SCOLR, Inc. 8340 154th AVE. N.E. Redmond, WA 98052-3864 March 18th, 2003 Attention: David T. Howard President and CEO This will confirm the understanding and agreement between Dunsford Hill Capital Partners ("Dunsford Hill" or the "Consultant") and...Consulting Agreement • March 31st, 2003 • Scolr Inc • In vitro & in vivo diagnostic substances
AGREEMENT ---------Credit Agreement • April 13th, 2000 • Synbiotics Corp • In vitro & in vivo diagnostic substances • California
RecitalsPurchase Agreement • February 7th, 2003 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
No. CS-1 October 30, 2003 PREDIX PHARMACEUTICALS HOLDINGS, INC. WARRANT FOR NEW COMMON STOCK THIS CERTIFIES THAT, for value received, RRD International, LLC, or its registered assigns (the "Holder"), is entitled, subject to the vesting provisions set...Warrant Agreement • November 9th, 2006 • EPIX Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • Delaware
RECITALSVoting Agreement • April 16th, 2004 • Boston Biomedica Inc • In vitro & in vivo diagnostic substances • Delaware
PLEDGE AGREEMENT PLEDGE AGREEMENT dated as of September 24, 1998 by and between Owen A. Dempsey, an individual with an address at 21 Harris Street, Brookline, Massachusetts 02146 (the "Pledgor"), in favor of Endogen, Inc., a Massachusetts corporation,...Pledge Agreement • January 14th, 1999 • Endogen Inc • In vitro & in vivo diagnostic substances • Massachusetts
COMMON STOCK PURCHASE WARRANT oncocyte corporationCommon Stock Purchase Warrant • April 19th, 2022 • Oncocyte Corp • In vitro & in vivo diagnostic substances • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [_____________] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on April 19, 2027 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Oncocyte Corporation, a California corporation (the “Company”), up to [●] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
EXHIBIT 10.1 ------------ SUBSCRIPTION AGREEMENT SUBSCRIPTION AGREEMENT (this "Agreement"), dated as of June 5, 2002, by and among Able Laboratories, Inc., a corporation organized under the laws of the State of Delaware (the "Company"), with...Subscription Agreement • August 9th, 2002 • Able Laboratories Inc • In vitro & in vivo diagnostic substances • Massachusetts
EXHIBIT 3 STOCK PURCHASE AGREEMENT AMENDMENT NO. 1 This Stock Purchase Agreement Amendment No. 1 (this "Amendment") dated as of July 15, 2003, is entered into by and among Estate of Gordon A. Cain (the "Estate"), RCM Financial Services, L.P., a...Stock Purchase Agreement • July 18th, 2003 • McNair Robert C • In vitro & in vivo diagnostic substances • Delaware
EXHIBIT 10.1 ------------------------------------------------------------------ -------------- LOAN AND SECURITY AGREEMENT --------------------------- -------- ------------------------------------------------------------------------Loan and Security Agreement • January 13th, 2000 • Dynagen Inc • In vitro & in vivo diagnostic substances • Massachusetts
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 3rd, 2024 • Oncocyte Corp • In vitro & in vivo diagnostic substances • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of October 2, 2024, between Oncocyte Corporation, a California corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
EXHIBIT 10.3 ALPHA INNOTECH CORPORATION EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the "AGREEMENT") is made and entered into as of May 11, 2001 by and between Alpha Innotech Corporation, a California corporation (the "COMPANY") and Haseeb...Employment Agreement • October 7th, 2005 • Alpha Innotech Corp • In vitro & in vivo diagnostic substances • California
EXHIBIT 10.05 AMENDMENT NO. 2 TO NOTE PURCHASE AGREEMENT THIS AMENDMENT NO. 2 (the "AMENDMENT"), dated as of January 28, 2003, is by and between INTERLEUKIN GENETICS, INC., a Delaware corporation (the "COMPANY"), and PYXIS INNOVATIONS INC., a Delaware...Note Purchase Agreement • March 5th, 2003 • Interleukin Genetics Inc • In vitro & in vivo diagnostic substances
EXHIBIT 10.11 THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF...Warrant Agreement • August 6th, 2004 • Adeza Biomedical Corp • In vitro & in vivo diagnostic substances • California
DISTRIBUTION AGREEMENT ---------------------- THIS AGREEMENT, made as of this 8th day of April, 1998 by and between Endogen Inc., a Massachusetts corporation having its principal place of business at 30 Commerce Way, Woburn, MA 01801-1059 (hereinafter...Distribution Agreement • August 28th, 1998 • Endogen Inc • In vitro & in vivo diagnostic substances • Massachusetts
N-MER, INC.Option Agreement • April 1st, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • California
AGREEMENTParticipation Agreement • May 15th, 2001 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Utah
amongMerger Agreement • February 11th, 2003 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • Delaware
BY AND AMONG HYSEQ, INC.,Merger Agreement • November 12th, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • Delaware
ARTICLE I. DEFINITIONSShare Purchase Agreement • November 7th, 2003 • Cytogen Corp • In vitro & in vivo diagnostic substances • Delaware
STOCK OPTION GRANTED BYStock Option Agreement • August 6th, 2004 • Able Laboratories Inc • In vitro & in vivo diagnostic substances • Delaware
BACKGROUNDSecurities Purchase Agreement • April 6th, 2006 • Synova Healthcare Group Inc • In vitro & in vivo diagnostic substances • Nevada
Exhibit 10.52 PURCHASE AND SALE AGREEMENT by and between PHL-OPCO, LP, a Delaware limited partnership, as Seller,Purchase and Sale Agreement • March 28th, 2001 • Medtox Scientific Inc • In vitro & in vivo diagnostic substances • Minnesota
INDENTUREIndenture • June 28th, 1999 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances • New York
EXHIBIT 1.1 10,000,000 SHARES LEXICON GENETICS INCORPORATED COMMON STOCK, $0.001 PAR VALUE PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • July 24th, 2003 • Lexicon Genetics Inc/Tx • In vitro & in vivo diagnostic substances • New York
